



# OFF-LABEL USE OF DALBAVANCIN IN REAL-WORLD CLINICAL PRACTICE: A RETROSPECTIVE OBSERVATIONAL STUDY

P. VEGA GONZÁLEZ<sup>1</sup>, D. GARCIA MARTÍNEZ<sup>1</sup>, N. GARRIDO PEÑO<sup>1</sup>, M. ANDRINO RODRÍGUEZ<sup>1</sup>, A. GONZÁLEZ FUENTES<sup>1</sup>, L.FERNANDEZ VALENCIA<sup>1</sup>, M. CARRERA SÁNCHEZ<sup>1</sup>, M. MAÑES SEVILLA<sup>1</sup>, M. SEGURA BEDMAR<sup>1</sup>.

<sup>1</sup>HOSPITAL UNIVERSITARIO DE MÓSTOLES, FARMACIA HOSPITALARIA, MADRID, SPAIN.

## BACKGROUND AND IMPORTANCE



Dalbavancin is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). However, its prolonged half-life and activity against Gram-positive pathogens have led to growing off-label use in complex infections. There is limited real-world data describing such use, particularly in secondary-level hospitals. Understanding these practices may support optimized antimicrobial stewardship and resource use.


## AIM AND OBJECTIVES



The primary objective was to describe off-label indications for dalbavancin and identify isolated microorganisms in patients treated at a secondary-level hospital. The secondary objective was to analyse patient characteristics and assess correlations between clinical variables and infection persistence or 90-day mortality.

## MATERIAL AND METHODS

STATA<sup>17</sup>



## RESULTS




### Off-label Use of Dalbavancin: Clinical Indications


**97.3% of usage is off-label.**

Out of 37 total patients, 36 received the drug for non-standard indications.

Off-label Indications by Percentage (%)



### Microbiological Isolates in Off-label Dalbavancin Use



## CONCLUSION AND RELEVANCE



Dalbavancin was predominantly used off-label, especially for osteoarticular and prosthetic infections. Its pharmacokinetics enabled outpatient management of severe infections, supporting continuity of care and hospital resource optimization. Age showed a non-significant trend toward infection persistence. Despite a limited sample size, these findings highlight dalbavancin's utility in complex infections and reinforce the role of hospital pharmacists in promoting its rational, personalized use.